Deerfield Management Company, L.P. (Series C) Merus N.V. Transaction History
Deerfield Management Company, L.P. (Series C)
- $4.76 Billion
- Q2 2024
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Merus N.V. stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 2,749,401 shares of MRUS stock, worth $130 Million. This represents 3.41% of its overall portfolio holdings.
Number of Shares
2,749,401
Previous 2,649,401
3.77%
Holding current value
$130 Million
Previous $119 Million
36.36%
% of portfolio
3.41%
Previous 2.46%
Shares
9 transactions
Others Institutions Holding MRUS
# of Institutions
188Shares Held
59MCall Options Held
345KPut Options Held
222K-
Rtw Investments, LP New York, NY4.17MShares$197 Million4.12% of portfolio
-
Commodore Capital LP New York, NY3.2MShares$151 Million16.98% of portfolio
-
Federated Hermes, Inc. Pittsburgh, PA2.4MShares$113 Million0.34% of portfolio
-
Samlyn Capital, LLC New York, NY2.32MShares$110 Million2.45% of portfolio
-
Franklin Resources Inc San Mateo, CA2.11MShares$99.4 Million0.04% of portfolio
About Merus N.V.
- Ticker MRUS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,878,200
- Market Cap $2.16B
- Description
- Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...